Laboratory markers of platelet activation and their clinical significance
- PMID: 10468151
- DOI: 10.1097/00062752-199909000-00012
Laboratory markers of platelet activation and their clinical significance
Abstract
Whole blood flow cytometry is a powerful new laboratory technique for assessment of platelet activation and function. Flow cytometry can be used to measure platelet hyperreactivity, circulating activated platelets, leukocyte-platelet aggregates, and procoagulant platelet-derived microparticles in a number of clinical settings, including acute coronary syndromes, angioplasty, cardiopulmonary bypass, acute cerebrovascular ischemia, peripheral vascular disease, diabetes mellitus, preeclampsia, and Alzheimer's disease. Clinical applications of whole blood flow cytometric assays of platelet function in these diseases may include identification of patients who would benefit from additional antiplatelet therapy and prediction of ischemic events. Circulating monocyte-platelet aggregates appear to be a more sensitive marker of in vivo platelet activation than circulating P-selectin-positive platelets. Flow cytometry can also be used in the following clinical settings: monitoring of glycoprotein IIb-IIIa antagonist therapy, diagnosis of inherited deficiencies of platelet surface glycoproteins, diagnosis of storage pool disease, diagnosis of heparin-induced thrombocytopenia, and measurement of the rate of thrombopoiesis.
Similar articles
-
Evaluation of platelet function by flow cytometry.Methods. 2000 Jul;21(3):259-70. doi: 10.1006/meth.2000.1006. Methods. 2000. PMID: 10873480
-
Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.Am J Cardiol. 1999 Sep 1;84(5):519-24. doi: 10.1016/s0002-9149(99)00370-7. Am J Cardiol. 1999. PMID: 10482148
-
Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.J Lab Clin Med. 2000 Mar;135(3):247-55. doi: 10.1067/mlc.2000.104907. J Lab Clin Med. 2000. PMID: 10711863
-
Platelets as predictors of vascular risk: is there a practical index of platelet activity?Clin Appl Thromb Hemost. 2003 Jul;9(3):177-90. doi: 10.1177/107602960300900301. Clin Appl Thromb Hemost. 2003. PMID: 14507105 Review.
-
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Vasc Health Risk Manag. 2006;2(1):39-48. doi: 10.2147/vhrm.2006.2.1.39. Vasc Health Risk Manag. 2006. PMID: 17319468 Free PMC article. Review.
Cited by
-
Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombogenic stimulus representing severe COVID-19.J Inflamm (Lond). 2022 Dec 30;19(1):28. doi: 10.1186/s12950-022-00325-8. J Inflamm (Lond). 2022. PMID: 36585712 Free PMC article.
-
Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.Arterioscler Thromb Vasc Biol. 2022 Oct;42(10):1207-1216. doi: 10.1161/ATVBAHA.122.318020. Epub 2022 Sep 1. Arterioscler Thromb Vasc Biol. 2022. PMID: 36047408 Free PMC article.
-
Platelet Toll-Like-Receptor-2 and -4 Mediate Different Immune-Related Responses to Bacterial Ligands.TH Open. 2022 Jul 11;6(3):e156-e167. doi: 10.1055/a-1827-7365. eCollection 2022 Jul. TH Open. 2022. PMID: 36046205 Free PMC article.
-
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccine.J Thromb Haemost. 2022 Apr;20(4):961-974. doi: 10.1111/jth.15648. Epub 2022 Jan 26. J Thromb Haemost. 2022. PMID: 35032087 Free PMC article.
-
Fundamentals in Covid-19-Associated Thrombosis: Molecular and Cellular Aspects.Front Cardiovasc Med. 2021 Dec 17;8:785738. doi: 10.3389/fcvm.2021.785738. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34977191 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
